News
News & Downloads
- Paradox of Health Care & Pharma Costs: Analysis of OECD economic and health data for nine countries. Newsletter
- Prevalence for P&R: impact on P&R decision? Newsletter
- pharmaLevers studies cited by Avenir Suisse:
Cosandey J und Estevez S., 2023. Wann sind neue Medikamente zu teuer? Raschen und finanzierbaren Zugang zu hochpreisigen Innovationen sichern. Avenir Suisse, Zürich. Online verfügbar: https://www.avenir-suisse.ch/publication/wann-sind-neue-medikamente-zu-teuer/
- Societal Perspective: a benefit dilution effect? Newsletter
- Pricing Models (MESs): Course or Blessing: Newsletter
- Swiss Cell-& Gene Therapy: different P&R processes: Newsletter
- Innovative Funding - Installment- & Amortization: Newsletter
- Cell & Gene Therapy - Budget Impact: Newsletter
- Cell & Gene Therapy - in a Nutshell: get insights from youtube video (2 min)
- Affordability - a new decade in health care: get insights from youtube video (8 min)
- Swiss Payer Study, Aug 2020: Proposed solutions for the handling of cost-intensive medicinesAre the applied pricing models and managed entry agreements (MEAs) for the 20 highest-selling medicines of 2019 sustainable and effective for the healthcare sector? What further optimizations would be appropriate to dampen the cost development? A narrative, solution-oriented approach from a cost object perspective.
Client: This study was commissioned by curafutura – The Innovative Health Insurers (click here for pdf)
- Brochure: Re-Evaluation - a continuos life cycle endeavor (Swiss Triennial Revison)
- pharmaLevers has developed the ISPOR GLOBAL HEALTH CARE SYSTEM ROAD MAP for Switzerland. The Pharmaceuticalsand Medical Devices road maps are no longer available on the ISPOR website - please contact pharmaLevers to get the road maps.